@Article{096504018X15344979253618,
AUTHOR = {Kai Zhang, Huajun Chen, Ye Wang, Lin Yang, Chengzhi Zhou, Weiqiang Yin, Guangsuo Wang, 
Xinru Mao, Jianxing Xiang, Bing Li, Tengfei Zhang, Shihong Fei},
TITLE = {Clinical Characteristics and Molecular Patterns of <i>RET</i>-Rearranged  Lung Cancer in Chinese Patients},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {5},
PAGES = {575--582},
URL = {http://www.techscience.com/or/v27n5/48573},
ISSN = {1555-3906},
ABSTRACT = {<i>RET</i> rearrangement has been proven as an oncogenic driver in patients with lung cancer. However, the prevalence, clinical characteristics, molecular features, and therapeutic options in <i>RET</i>-rearranged patients remain 
unclear, especially in Chinese lung cancer patients. We retrospectively collected 6,125 Chinese lung cancer 
patients who have been profiled using next-generation sequencing (NGS). The clinical demographics and 
molecular features of <i>RET</i> rearrangement-positive patients were analyzed. <i>RET</i> rearrangements were identified in 84 patients with a proportion of 1.4% in our cohort. The median age at diagnosis was 58 years, and it 
mainly occurred in females with adenocarcinoma histology. <i>KIF5B-RET</i> was the most frequent fusion type 
and accounted for 53.8% (57/106) of all <i>RET</i> fusions identified, with K15-R12 as the most frequent variant (71.9%). Among 47 <i>RET</i>+
 patients profiled with larger panels, 72.3% (34/47) harbored concurrent alterations. TP53 ranked as the most common concurrent alteration, and concomitant EGFR oncogenic alterations 
were identified in seven patients. Moreover, an adenocarcinoma patient harboring concurrent <i>RET</i> fusion and 
EGFR L858R responded to combinatorial treatment of cabozantinib and osimertinib, with a progression-free 
survival of 5 months. Our study improved knowledge of clinical characteristics and molecular features of 
<i>RET</i>-rearranged lung cancers in China. It might be helpful to guide clinicians for more effective personalized 
diagnostic and therapeutic approaches.},
DOI = {10.3727/096504018X15344979253618}
}